Terms: = Ovarian cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
34 results:
1. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer.
Tang Q; Atiq W; Mahnoor S; Abdel-Maksoud MA; Aufy M; Yaz H; Zhu J
Oncol Res; 2023; 31(2):141-156. PubMed ID: 37304238
[TBL] [Abstract] [Full Text] [Related]
3. Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer.
Bercow AS; Rauh-Hain JA; Melamed A; Mazina V; Growdon WB; Del Carmen MG; Goodman A; Bouberhan S; Randall T; Sisodia R; Bregar A; Eisenhauer EL; Minami C; Molina G
Gynecol Oncol; 2023 Feb; 169():47-54. PubMed ID: 36508758
[TBL] [Abstract] [Full Text] [Related]
4. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M; Shu Y; Chen G; Li J; Li F
Sci Rep; 2022 Nov; 12(1):20601. PubMed ID: 36446798
[TBL] [Abstract] [Full Text] [Related]
5. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract] [Full Text] [Related]
6. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
Filippova OT; Tin AL; Alonso J; Vickers AJ; Tew WP; Gardner GJ; Sonoda Y; Roche KL; Zivanovic O; Chi DS; Shahrokni A
Gynecol Oncol; 2021 Jun; 161(3):687-692. PubMed ID: 33773807
[TBL] [Abstract] [Full Text] [Related]
7. Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Arend RC; Monk BJ; Herzog TJ; Moore KN; Shapira-Frommer R; Ledermann JA; Tewari KS; Secord AA; Rachmilewitz Minei T; Freedman LS; Miller A; Shmueli SF; Lavi M; Penson RT
Gynecol Oncol; 2021 May; 161(2):496-501. PubMed ID: 33637348
[TBL] [Abstract] [Full Text] [Related]
8. Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
Majidi A; Na R; Jordan SJ; De Fazio A; Webb PM;
Int J Cancer; 2021 Apr; 148(7):1608-1615. PubMed ID: 33034053
[TBL] [Abstract] [Full Text] [Related]
9. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.
Costa OS; Kohn CG; Kuderer NM; Lyman GH; Bunz TJ; Coleman CI
Blood Adv; 2020 Sep; 4(17):4045-4051. PubMed ID: 32853381
[TBL] [Abstract] [Full Text] [Related]
10. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.
Kaspers M; Llamocca E; Quick A; Dholakia J; Salani R; Felix AS
Am J Obstet Gynecol; 2020 Sep; 223(3):398.e1-398.e18. PubMed ID: 32142825
[TBL] [Abstract] [Full Text] [Related]
11. Other- and all-cause Mortality among women with breast cancer.
Pierre-Victor D; Pinsky PF; McCaskill-Stevens W
Cancer Epidemiol; 2020 Apr; 65():101694. PubMed ID: 32135504
[TBL] [Abstract] [Full Text] [Related]
12. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
13. Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta-analysis.
Zhang C; Hou W; Huang J; Yin S; Wang P; Zhang Z; Tan Y; Xu H
J Cell Biochem; 2019 Sep; 120(9):14486-14498. PubMed ID: 31050365
[TBL] [Abstract] [Full Text] [Related]
14. Assessment of Tumor Redox Status through (
McCormick PN; Greenwood HE; Glaser M; Maddocks ODK; Gendron T; Sander K; Gowrishankar G; Hoehne A; Zhang T; Shuhendler AJ; Lewis DY; Berndt M; Koglin N; Lythgoe MF; Gambhir SS; Årstad E; Witney TH
Cancer Res; 2019 Feb; 79(4):853-863. PubMed ID: 30401715
[TBL] [Abstract] [Full Text] [Related]
15. Survival Impact of ovarian Preservation on Women With Early-Stage Endometrial cancer: A Systematic Review and Meta-analysis.
Gu H; Li J; Gu Y; Tu H; Zhou Y; Liu J
Int J Gynecol Cancer; 2017 Jan; 27(1):77-84. PubMed ID: 27922977
[TBL] [Abstract] [Full Text] [Related]
16. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis.
Mei L; Hou Q; Fang F; Wang H
Eur J Gynaecol Oncol; 2016 Aug; 37(4):455-460. PubMed ID: 29894066
[TBL] [Abstract] [Full Text] [Related]
17. Cyclin-Dependent Kinase 11 (CDK11) Is Required for ovarian cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract] [Full Text] [Related]
18. cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract] [Full Text] [Related]
19. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Tewari KS; Java JJ; Eskander RN; Monk BJ; Burger RA
Ann Oncol; 2016 Jan; 27(1):114-21. PubMed ID: 26487588
[TBL] [Abstract] [Full Text] [Related]
20. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
Montero JC; García-Alonso S; Ocaña A; Pandiella A
Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
[TBL] [Abstract] [Full Text] [Related]
[Next]
